Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philips Intera MR Subject Of Warning Letter For Unapproved Perfusion Claim

This article was originally published in The Gray Sheet

Executive Summary

FDA's recent warning letter to Philips Medical regarding promotion of magnetic resonance (MR) scanners for cardiac perfusion studies is symptomatic of the industry's struggle to find a regulatory pathway to approval for the indication

You may also be interested in...



Philips Medical Systems Incurs Second Warning Letter Since August

Corrective actions related to a warning letter Philips Medical Systems received Oct. 16 will be addressed during a meeting between the company and FDA the week of Nov. 3

Philips Medical Systems Incurs Second Warning Letter Since August

Corrective actions related to a warning letter Philips Medical Systems received Oct. 16 will be addressed during a meeting between the company and FDA the week of Nov. 3

CDRH Review Of Expanded Imaging Agent Indications Urged By NEMA

CDRH should serve as the lead reviewer for premarket applications of already-approved contrast agents indicated for use with diagnostic imaging devices, according to Philips Medical Systems VP-Quality & Regulatory Affairs Terry Sweeney

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel